# Case Challenges in HIV/HCV Management

Todd S. Wills, MD Infectious Disease Specialist HRSA SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center at University of South Florida



HEPATITIS C TREATMENT EXPANSION INITIATIVE 2<sup>nd</sup> ANNUAL ALL GRANTEE MEETING WASHINGTON, DC - NOVEMBER 29<sup>th</sup> - 30<sup>th</sup> 2011



## **Determining Treatment Candidacy**

- 36 year old black female
- HIV Diagnosed in 2002 Nadir CD4 180 cells/mm3
- History of IVDA (heroin)
- Diagnosed with HCV 2002 no previous workup



## **Determining Treatment Candidacy**

- Other Medical History DM2, depression
- Social History Smokes 1 PPD, prior IVDA, married with 2 children – sexually active
- Medications:
- Zidovudine, lamivudine, lopinavir/ritonavir
- Metformin 500 mg daily, sertraline 50 mg daily, methadone 40 mg daily





## **Determining Treatment Candidacy**

- BMI 29
- Exam no stigmata of liver disease

LAB	RESULT	LAB	RESULT
Hemoglobin	11 g/dL	HIV load	<50 copies/mL
ANC	900 cell/mm <sup>3</sup>	CD4 count	370 cells/mm <sup>3</sup>
Platelets	140,000/mm <sup>3</sup>	HCV viral load	1.7 million copies/mL
Hgb A1C	9.0 %	HCV genotype	1a
Total bilirubin	0.7 mg/dL	INR	1.05
ALT/AST	33/38 U/L	HAV Ab	+
creatinine	0.7 mg/dL	HBV SAg/core/SAb	-/+/-



**SA** HEPATITIS C TREATMENT EXPANSION INITIATIVE 2<sup>nd</sup> ANNUAL ALL GRANTEE MEETING WASHINGTON, DC – NOVEMBER 29<sup>th</sup> – 30<sup>th</sup> 2011



#### Patient-level Topics for Consideration

- Indications, contraindications or barriers to HCV treatment?
- Further work-up?
- Medication Adjustments?
- Timing of treatment?



# **Clinic-level Topics for Consideration**

- What support services may be necessary to assist in treatment initiation and maintenance?
- What additional services (medical or ancillary) are located on-site or off-site at your clinic? How does this affect your management strategy?



#### **Treatment Initiation**

- Antiretroviral therapy is changed to tenofovir/emtricitabine from zidovodine/lamivudine plus lopinavir/ritonavir
- Psychiatry evaluation: sertraline dose changed to 100 mg daily





### Patient-Level Discussion Points

- What expectations for weight and glycemic control govern your decision to initiate therapy?
- What HCV treatment regimen would you start?





#### **Treatment Initiation**

- Therapy is started with:
  - Pegylated interferon alfa 2a 180 mcg sq weekly
  - ribavirin 600 mg po bid
- Week 4 labs: (PHQ-9 score 8 baseline 5)

LAB	RESULT
Hgb	10.2 g/dL
ANC	650 cells/mm <sup>3</sup>
Platelets	97,000/ mm <sup>3</sup>
HCV viral load	17,000 copies/mL



**5A** HEPATITIS C TREATMENT EXPANSION INITIATIVE 2<sup>nd</sup> ANNUAL ALL GRANTEE MEETING WASHINGTON, DC – NOVEMBER 29<sup>th</sup> – 30<sup>th</sup> 2011



### **Patient-Level Discussion Points**

- What is the significance of the week 4 HCV viral load?
- Any treatment modifications or additions based on these results?





#### **Treatment Continuation**

• Treatment Week 12 Labs: (PHQ-9 Score: 11)

LAB	RESULT	
Hemoglobin	10.2 g/dL	
ANC	700 cells/mm <sup>3</sup>	
Platlets	78,000/mm <sup>3</sup>	
HCV Viral Load	<43 copies/mL	
CD4 Count	188 cells/mm <sup>3</sup> (22%)	
HIV Viral Load	<20 copies/mL	



**5A** HEPATITIS C TREATMENT EXPANSION INITIATIVE 2<sup>nd</sup> ANNUAL ALL GRANTEE MEETING WASHINGTON, DC – NOVEMBER 29<sup>th</sup> – 30<sup>th</sup> 2011



### **Patient-Level Discussion Points**

- What is the significance of the week 12 HCV viral load?
- Any treatment modifications or additions based on these results?



